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Abstract
Background: Aspirin and clopidogrel monotherapies are effective treatments for preventing vascular disease. However, new
evidence has emerged regarding the use of combined aspirin and clopidogrel therapy to prevent cardiovascular events. We
therefore performed a comprehensive systematic review and meta-analysis to evaluate the benefits and harms of combined
aspirin and clopidogrel therapy on major cardiovascular outcomes.
Methodology/Principal Findings: We systematically searched Medline, Embase, the Cochrane Central Register of Controlled
Trials, reference lists of articles, and proceedings of major meetings to identify studies to fit our analysis. Eligible studies
were randomized controlled trials assessing the effect of combined aspirin and clopidogrel therapy compared with aspirin
or clopidogrel monotherapy. We identified 7 trials providing data with a total of 48248 patients. These studies reported
5134 major cardiovascular events, 1626 myocardial infarctions, 1927 strokes, and 1147 major bleeding events. Overall, the
addition of aspirin to clopidogrel therapy as compared to single drug therapy resulted in a 9% RR reduction (95%CI, 2 to 17)
in major cardiovascular events, 14% RR reduction (95%CI, 3 to 24) in myocardial infarction, 16% RR reduction (95%CI, 1 to
28) in stroke, and 62% RR increase (95%CI, 26 to 108) in major bleeding events. We also present the data as ARR to explore
net value as the reduction in cardiovascular events. Overall, we observed that combined therapy yielded 1.06% decrease
(95%CI, 0.23% to 1.99%) in major cardiovascular events and 1.23% increase (95%CI, 0.52% to 2.14%) in major bleeding
events.
Conclusion/Significance: Although the addition of aspirin to clopidogrel resulted in small relative reductions in major
cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events. In
absolute terms the benefits of combined therapy, a 1.06% reduction in major cardiovascular events, does not outweigh the
harms, a 1.23% increase in major bleeding events.
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Introduction
Cardiovascular disease is the leading cause of premature
morbidity and mortality worldwide for both men and women
[1], accounting for 30.9% of global mortality and 10.3% of the
global burden of disease [2]. Antiplatelet therapy, which is
recommended as the standard practice [3], can reduce the harm
of cardiovascular disease in patients with peripheral arterial
disease. However, its effects in patients with cardiovascular harm
factors remain unclear. Over the past decades, several studies
[4–6] have demonstrated that aspirin is effective in the prevention
of cardiovascular events, and long-term aspirin therapy reduces
the annual harm of serious vascular disease by approximately 25%
[7]. Recently, clopidogrel (Plavix; Sanofi-Aventis and Bristol-
Myers Squibb) has emerged as a new drug commonly used for the
secondary prevention of cardiovascular disease, and evidence [8]
shows that clopidogrel therapy is superior to aspirin for the
secondary prevention of serious vascular events. However, in
many cases, aspirin or clopidogrel therapy alone is not sufficient to
prevent ischemic events in patients at high harm [9]. It is necessary
to develop additional effective preventive therapies.
The goals of prevention for cardiovascular events are anti-
thrombus and platelet aggregation, for which both aspirin and
clopidogrel are promising. Clinical efficacy of these drugs for
reducing serious vascular events and mortality in patients with
high harm has been shown in several large-scale clinical trials
[10,11]. However, whether dual antiplatelet therapy with aspirin
plus clopidogrel is more effective than a single antiplatelet agent in
patients with high harm remains uncertain.
Recently, several large-scale randomized controlled trials in-
vestigating the use of aspirin combined with clopidogrel therapy
have been performed [12–14]. Some trials indicated that
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effect and some studies even found that combined therapy could
induce drug-related adverse reactions, such as bleeding events.
This leads to uncertainty regarding the cardiovascular protective
effects of combined therapy, which makes interpretation of the
results difficult for clinicians. To better understand the effect of
combined therapy on cardiovascular outcomes, data from these
recent trials needed to be evaluated to formulate a conclusion
regarding the efficacy of combined therapy. We therefore
conducted a systematic review and meta-analysis of pooled data
from randomized controlled trials, including the latest evidence of
the association of aspirin plus clopidogrel therapy on the harm of
serious vascular events and any possible adverse reactions in
patients with high cardiovascular harm factors.
Methods
Data sources, search strategy, and selection criteria
We gathered data from randomized controlled trials to assess
the effect of combined aspirin with clopidogrel therapy on the
harm of cardiovascular outcomes. To be consistent with other
large-scale meta-analysis protocols, we included trials comparing
combined therapy with a control, excluding any studies with a
follow-up period of less than 12 months, in order to alleviate
systematic error and resultant bias, and ensure the reliability of our
conclusion.
Randomized controlled trials and literature reporting trials of
combined therapy in English met the eligibility criteria for our
meta-analysis, regardless of publication status (published, unpub-
lished, in press or in progress). Relevant trials were identified with
the following procedure:
(1) Electronic searches: We searched PubMed, EmBase, and the
Cochrane Central Register of Controlled Trials with a date up
to March 20, 2011. We use the terms of ‘‘aspirin’’ OR
‘‘clopidogrel’’ AND ‘‘clinical trial’’.
(2) Other sources: We contacted authors to obtain any possible
additional published or unpublished data and searched the
proceedings of the annual meeting in the Cochrane
Cardiovascular Disease Group Specialized Register. Further-
more, we searched ongoing randomized controlled trials in
the metaRegister of Controlled Trials, which lists trials that
are registered as completed but not yet published. In addition,
we reviewed bibliographies of publications for potentially
relevant articles. Medical subject headings, methods, patient
populations, interventions and outcome variables of these
trials were used. This review was conducted and reported
according to the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analysis) Statement issued in
2009 (Checklist S1) [15].
All included trials evaluated the development of serious vascular
events after treatment with active or control therapy. In addition,
we excluded all studies with less than 100 patients and less than
12-month follow-up. Further, identified trials should report on one
or more of the following primary or secondary outcomes: major
cardiovascular events, myocardial infarction, stroke, mortality,
major bleeding events, and other possible adverse reaction.
Data collection and quality assessment
The identified 7,038 studies were reviewed by 2 authors (Xin
Wei and Mei-Jing. Wu) independently. Other two reviewers (Jin-
Fang. Xu and Jian Lu) independently checked each full-text trial
for eligibility and extracted and tabulated all relevant data with a
standardized flow path. Extracted data included the year of
publication, the number of patients enrolled, interventions,
primary or secondary prevention protocols, cardiovascular harm
factors, the duration of follow-up, and outcome events. Disagree-
ments regarding the data were settled by consensus between all
authors. Additional tabular data were retrieved by direct contact
with the corresponding authors and discrepancies in the data were
corrected when a consensus was reached. Study quality was
assessed using the Jadad score [16] (Yu-Hao. Zhou) on
randomization, concealment of the treatment allocation, blinding,
completeness of follow-up, and the use of intention-to-treat
analysis.
Statistical analysis
We allocated the results of each randomized controlled trial as
dichotomous frequency data. Individual study relative risks (RRs)
and 95% confidence intervals (CIs) were calculated from event
numbers extracted from each trial before data pooling. The overall
relative risk (RR) with 95% CIs of serious vascular events and any
possible adverse reaction was also calculated. Although the fixed-
effect and random-effects models yielded similar conclusions, we
chose the random-effects model with Mantel-Haenszel statistics for
the meta-analysis, which assumed that the true underlying effect
varies among included trials. Moreover, many investigators also
consider the random-effects model to be a more natural choice
than the fixed-effect model in medical decision-making contexts
[17,18]. The variability, expressed in percentage, across studies
attributable to heterogeneity beyond chance was estimated with
the I
2 statistic [19]. Egger’s test [20] was used to check for
potential publication bias. We explored potential heterogeneity in
estimates of treatment effect with univariate meta-regression. We
also performed subgroup analysis by mean age, follow-up years,
and study quality. All reported P values were two-sided and P
values of less than 0.05 were regarded as significant for all included
studies. Statistical analyses were carried out using STATA (version
10.0).
Results
We identified 7,038 potential studies from our systematic
review, and 6,903 of them were excluded after a preliminary
review of searches. The remaining 135 studies were retrieved for
detailed assessment. Of these, 7 randomized controlled trials met
our inclusion criteria (Figure 1 and Protocol S1 [15]). 6 of these
evaluated combined therapy comparing with aspirin therapy alone
[9,12–14,21,22] and the other one study [23] evaluated combined
therapy comparing with clopidogrel alone. The 7 trials provided
data of 48,248 patients (mean, 6,893 patients and range from 113
to 15,603). Table 1 summarizes the baseline characteristics of
the included studies and their participants. The primary outcomes
were major cardiovascular events available in 6 trials, myocardial
infarction in 7 trials, stroke in 7 trials, total mortality in 6
trials, vascular death in 4 trials, nonvascular death in 4 trials,
revascularization in 2 trials, and major bleeding in 6 trials.
Although the included trials scarcely reported on the key
indicators of trial quality, the quality of the trials was also assessed
according to the pre-fixed criteria using the Jadad score. Overall,
two trials scored 5, two trials scored 4, and the remaining three
trials scored 3.
Data for the effect of combined aspirin and clopidogrel therapy
on major cardiovascular events were available from 6 trials, which
included 46,132 patients and reported 5,134 serious vascular
events (Figure 2). Overall, we observed that with combined
therapy, the harm of major cardiovascular events was significantly
Aspirin and Clopidogrel on Cardiovascular Outcomes
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single drug therapy.
Data for the effect of aspirin combined with clopidogrel therapy
on myocardial infarction were available from 7 trials, including
48,248 patients and 1,626 events of myocardial infarction
(Figure 3).
Combined therapy resulted in a 14% reduction in the harm of
myocardial infarction compared with single drug therapy (RR,
0.86; 95% CI, 0.76 to 0.97).
Data for the effect of aspirin combined with clopidogrel therapy
on stroke were available from 7 trials, which included 48,248
patients and reported 1,927 stroke events (Figure 4). Overall,
combined therapy reduced the harm of stroke by 16% when
compared with single drug therapy (RR, 0.84; 95% CI, 0.72 to
0.99).
Six trials reported the effect of aspirin combined with
clopidogrel therapy on total mortality, which including 35,686
patients and recorded 2,889 deaths (Table 2). Of the included
trials, 4 trials reported separate data for vascular death (27,828
patients and 2,108 vascular deaths) and 4 trials provided separate
data for nonvascular death (27,828 patients and 710 nonvascular
deaths). Overall, there was no evidence to show that combined
therapy could reduce the risk of mortality, regardless of total
mortality, vascular death, or non-vascular death.
The effect of aspirin combined with clopidogrel therapy on the
harm of revascularization was reported in 2 trials, which included
4,817 patients and recorded 345 revascularization events. Overall,
there was no effect of combined therapy on the harm of
revascularization events compared with single drug therapy
(Table 2).
We observed that the primary adverse outcome was major
bleeding and this outcome was record by 7 trials (46,073
participants and 1,147 major bleeding events, Figure 5). Overall,
combined therapy increased the harm of major bleeding events by
62% when compared with single drug therapy (RR, 1.62; 95% CI,
1.26 to 2.08).
Although combined therapy present beneficial effect than single
drug therapy in reducing the harm of major cardiovascular events,
myocardial infarction, or stroke, it also significantly increased the
harm of major bleeding events. Therefore, we have present the
data as absolute risk reduction (ARR) and its confidence intervals
to explore net value as the reduction in cardiovascular events,
which weighted against any increase in major bleeding events.
Overall, the outcome measuring benefit is total cardiovascular
Figure 1. Flow diagram of the literature search and trials selection process.
doi:10.1371/journal.pone.0031642.g001
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events, and 95% confidence intervals ranged from 0.23% to
1.99%. Similarly, the outcome measuring harm comes from major
bleeding events, and the pooled ARR showed 1.23%, 95%
confidence intervals ranged from 0.52% to 2.14%, we noted that
the benefits ARR was not associated with a statistically significant
difference compared with harms ARR, which indicated that the
benefits do not outweigh the harms for combined therapy.
We noted evidence of heterogeneity in the magnitude of the
effect across the included trials for major cardiovascular events,
myocardial infarction, stroke, and major bleeding. Therefore, we
performed a subgroup analysis to minimize the consequences of
heterogeneity among the included trials based on control drugs
(Table 2). In addition, we also performed a subgroup analysis for
combined therapy compared with different drug therapy based on
mean age, follow-up years, and study quality (Table 3). Overall,
aspirin combined with clopidogrel therapy was not associated with
a reduction in the harm of major cardiovascular events compared
with aspirin therapy alone when mean age of included trials was
less than 65, follow-up was less than 24 months, and the Jadad
Figure 2. Effects of aspirin with clopidogrel therapy on risk of major cardiovascular events.
doi:10.1371/journal.pone.0031642.g002
Table 1. Design and characteristic of trials included in the systematic review and meta-analysis.
Source
No. of
patients
Mean
age, y
Sex
(male) Inclusion criteria
Primary/
secondary
prevention Intervention
Duration of
follow-up
(months)
Jaded
score
The CURE
Investigators [9]
12562 64.2 7726
(61.5%)
acute coronary
syndromes without
ST-segment elevation
secondary (1)Clopidogrel (75 mg daily) plus
Aspirin (75 to 325 mg daily)
(2)Aspirin (75 to 325 mg daily)
12 4
SJ Park 2010 [12] 2701 62.0 1883
(69.7%)
Stents used .
12 month
secondary (1)Clopidogrel (75 mg daily) plus
Aspirin (100 to 200 mg daily)
(2) Aspirin (100 to 200 mg daily)
19.2 3
The ACTIVE
Investigators [13]
7554 71.0 4397
(58.2%)
atrial fibrillation secondary (1)Clopidogrel (75 mg daily) plus
Aspirin (75 to 100 mg daily)
(2) Aspirin (75 to 100 mg daily)
43.2 4
CASCADE
Trial [14]
113 66.5 101
(89.4%)
coronary artery
bypass grafting
secondary (1)Clopidogrel (75 mg daily)
plus Aspirin (162 mg daily)
(2) Aspirin (162 mg daily)
12 5
CHARISMA
Investigators [21]
15603 64.0 10959
(70.2%)
multiple
atherothrombotic
risk factors
secondary (1)Clopidogrel (75 mg daily) plus
Aspirin (75 to 162 mg daily)
(2) Aspirin (75 to 162 mg daily)
28 3
CREDO
Investigators [22]
2116 61.7 1510
(71.4%)
Privious PCI secondary (1)Clopidogrel (75 mg daily) plus
Aspirin (81 to 325 mg daily)
(2) Aspirin (81 to 325 mg daily)
12 5
MATCH
investigators [23]
7599 66.3 4778
(62.9%)
at least one
vascular risk factor
secondary (1)Clopidogrel (75 mg daily) plus
Aspirin (75 mg daily)
(2) Clopidogrel (75 mg daily)
18 3
doi:10.1371/journal.pone.0031642.t001
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combined therapy was comparative to that with aspirin therapy
alone when mean age of the included trials was more than 65,
follow-up was more than 24 months, and the Jadad score was less
than 4. Similarly, the harm of stroke was not significantly reduced
when follow-up of the included trials was less than 24 months and
the Jadad score was less than 4. Further, the harm of major
bleeding events was ineffectively reduced when the Jadad score of
the included trials was less than 4.
We used Egger’s test to check for potential publication bias,
which showed no evidence of publication bias for the outcomes of
major cardiovascular events (P value for Egger’s test, 0.674) and
myocardial infarction (P value for Egger’s test, 0.674). However,
we noted evidence of publication bias for stroke (P value for
Egger’s test, 0.012) and major bleeding events (P value for Egger’s
test, 0.011). The conclusions were not changed after adjustment
for publication bias by the trim and fill method [24].
Discussion
Recently, evidence from large-scale randomized controlled trials
[12,14] has shown that aspirin plus clopidogrel therapy is not
significantly more effective than aspirin alone in reducing the rate
of major cardiovascular events. In addition, the harm of life-
threatening or major bleeding events has been shown to increase
with combined therapy [23]. Our study has shown a possible
incremental benefit of adding aspirin to clopidogrel therapy in
reducing the harm of major cardiovascular events, myocardial
infarction, or stroke. However, the benefits do not outweigh the
harms (major bleeding events), when these 2 drugs are given in
combination.
The results of our meta-analysis showed that patients assigned
aspirin combined with clopidogrel therapy could have reduced
harms of major cardiovascular events, myocardial infarction, and
stroke, when compared with aspirin therapy alone. However,
Figure 4. Effects of aspirin with clopidogrel therapy on risk of stroke.
doi:10.1371/journal.pone.0031642.g004
Figure 3. Effects of aspirin with clopidogrel therapy on risk of myocardial infarction.
doi:10.1371/journal.pone.0031642.g003
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clopidogrel therapy in the relative risk for major cardiovascular
events, myocardial infarction, or stroke. The reason for this could
be that only 1 trial in such subset. Furthermore, combined therapy
significantly increased the harm of major bleeding events, when
compared with aspirin or clopidogrel alone. These conclusions are
in accordance with the results of some individual trials [12–14],
which recently reported on the incremental benefit of combined
therapy on cardiovascular outcomes and the synergistic effect on
major bleeding events. Moreover, we also present the data as
absolute risk reduction (ARR) and its confidence intervals to
explore clearly that the benefits do not outweigh the harms for
combined therapy.
According to the CURE trials [9], dual antiplatelet therapy with
clopidogrel plus aspirin had beneficial effects on the harm of major
cardiovascular events compared with aspirin therapy alone, but
there were also significantly more patients with major bleeding
events in the combined therapy group than in the aspirin-alone
group. Furthermore, the CHARISMA trial [21] showed that
clopidogrel plus aspirin therapy was not significantly more
effective than aspirin therapy alone in reducing the rate of major
cardiovascular events, myocardial infarction, stroke, and death
from vascular disease. Moreover, combined therapy also played an
important role in increasing the harm of major bleeding events,
whether compared with aspirin or clopidogrel therapy. Our
research has defined that benefits could be achieved through the
administration of aspirin plus clopidogrel therapy to patients with
a history of vascular disease or other vascular-related diseases, in
addition, we also noted that adding aspirin to clopidogrel therapy
significantly increased the harm of major bleeding events, whether
Figure 5. Effects of aspirin with clopidogrel therapy on risk of major bleeding events.
doi:10.1371/journal.pone.0031642.g005
Table 2. Evidence profile for Aspirin and Clopidogrel on the risk of vascular events.
Intervention
group (events/
total patients)
Control group
(events/total
patients) RR (95% CI)
P
value
I
2
(%)
P value for
heterogeneity
Major cardiovascular
events
Aspirin with clopidogrel vs aspirin alone 1980/19246 2236/19287 0.90 (0.81, 1.00) 0.04 55 0.07
Aspirin with clopidogrel vs clopidogrel 445/3797 473/3802 0.94 (0.83, 1.06) 0.33 - -
MI Aspirin with clopidogrel vs aspirin alone 644/20299 787/20350 0.83 (0.74, 0.93) 0.001 9 0.36
Aspirin with clopidogrel vs clopidogrel 73/3797 68/3802 1.07 (0.77, 1.49) 0.67 - -
Stroke Aspirin with clopidogrel vs aspirin alone 539/20299 702/20350 0.77 (0.69, 0.86) ,0.001 3 0.40
Aspirin with clopidogrel vs clopidogrel 339/3797 347/3802 0.98 (0.85, 1.13) 0.76 - -
Total mortality Aspirin with clopidogrel vs aspirin alone 1234/14040 1253/14047 0.99 (0.92, 1.06) 0.70 0 0.61
Aspirin with clopidogrel vs clopidogrel 201/3797 201/3802 1.00 (0.83, 1.21) 0.99 - -
Vascular death Aspirin with clopidogrel vs aspirin alone 918/10087 945/10142 0.98 (0.90, 1.0 6) 0.61 0 0.56
Aspirin with clopidogrel vs clopidogrel 124/3797 121/3802 1.03 (0.80, 1.31) 0.84 - -
nonvascular death Aspirin with clopidogrel vs aspirin alone 266/10087 287/10142 0.93 (0.79, 1.09) 0.38 0 0.95
Aspirin with clopidogrel vs clopidogrel 77/3797 80/3802 0.96 (0.71, 1.31) 0.82 - -
revascularization Aspirin with clopidogrel vs aspirin alone 175/2410 170/2407 1.07 (0.79, 1.44) 0.65 34 0.22
Major bleeding Aspirin with clopidogrel vs aspirin alone 616/19246 436/19287 1.42 (1.26, 1.60) ,0.001 0 0.64
Aspirin with clopidogrel vs clopidogrel 73/3759 22/3781 3.34 (2.08, 5.36) ,0.001 - -
doi:10.1371/journal.pone.0031642.t002
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treatment with aspirin and clopidogrel agents.
Subgroup
Intervention
group
Control
group
RR
(95% CI) P value
P value for
heterogeneity
Major
cardiovascular
events
Aspirin with clopidogrel
vs aspirin alone
Mean age
.65 836/3828 929/3839 0.90 (0.83, 0.98) 0.01 0.87
,65 1144/15418 1307/15448 0.93 (0.76, 1.13) 0.46 0.01
Follow-up (month)
.24 1366/11574 1497/11583 0.91 (0.85, 0.98) 0.007 0.66
,24 614/7672 739/7704 1.07 (0.58, 1.97) 0.82 0.04
Jadad score
4 or 5 1418/10087 1648/10142 0.87 (0.80, 0.93) 0.0001 0.31
,4 562/9159 588/9145 1.22 (0.63, 2.36) 0.55 0.03
Aspirin with clopidogrel
vs clopidogrel
none 445/3797 473/3802 0.94 (0.83, 1.06) 0.33 -
MI Aspirin with clopidogrel
vs aspirin alone
Mean age
.65 94/3828 116/3839 1.24 (0.29, 5.31) 0.77 0.14
,65 550/16471 671/16511 0.83 (0.73, 0.94) 0.002 0.35
Follow-up (month)
.24 236/11574 270/11583 0.87 (0.73, 1.04) 0.13 0.31
,24 408/8725 517/8767 0.81 (0.67, 0.97) 0.03 0.30
Jadad score
4 or 5 488/11140 625/11205 0.78 (0.70, 0.88) ,0.0001 0.52
,4 156/9159 162/9145 0.96 (0.77, 1.20) 0.73 0.42
Aspirin with clopidogrel
vs clopidogrel
none 73/3797 68/3802 1.07 (0.77, 1.49) 0.67 -
Stroke Aspirin with clopidogrel
vs aspirin alone
Mean age
.65 296/3828 410/3839 0.73 (0.63, 0.84) ,0.0001 0.41
,65 243/16471 292/16511 0.83 (0.70, 0.99) 0.03 0.39
Follow-up (month)
.24 446/11574 597/11583 0.75 (0.66, 0.84) ,0.0001 0.50
,24 93/8725 105/8767 0.91 (0.62, 1.33) 0.62 0.33
Jadad score
4 or 5 380/11140 509/11205 0.75 (0.66, 0.85) ,0.0001 0.62
,4 159/9159 193/9145 1.12 (0.43, 2.93) 0.81 0.09
Aspirin with clopidogrel
vs clopidogrel
none 339/3797 347/3802 0.98 (0.85, 1.13) 0.76 -
Major bleeding
events
Aspirin with clopidogrel
vs aspirin alone
Mean age
.65 252/3828 162/3839 1.56 (1.29, 1.89) ,0.0001 0.68
,65 364/15418 274/15448 1.33 (1.14, 1.56) 0.0003 0.66
Follow-up (month)
.24 381/11574 266/11583 1.42 (1.15, 1.75) 0.001 0.18
,24 235/7672 170/7704 1.39 (1.14, 1.69) 0.0009 0.71
Jadad score
4 or 5 483/10087 331/10142 1.47 (1.28, 1.68) ,0.0001 0.62
,4 133/9159 105/9145 1.26 (0.98, 1.63) 0.07 0.46
Aspirin with clopidogrel
vs clopidogrel
none 73/3759 22/3781 3.34 (2.08, 5.36) ,0.001 -
doi:10.1371/journal.pone.0031642.t003
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and its cobfidence intervals, we easy concluded that combined
therapy provided the benefits do not outweigh the harms, which
provided by adding aspirin to clopidogrel therapy
Subgroup analysis was also performed, which revealed that
high-quality (Jadad score 4 or 5) trials suggested that the harms of
major cardiovascular events, myocardial infarction, and stroke
were significantly reduced by combined therapy compared with
aspirin alone. However, although some beneficial effects on the
harm of cardiovascular disease were revealed, aspirin plus
clopidogrel therapy also significantly increased the harm of major
bleeding events, translating into an increased harm of life-
threatening events. The low-quality (Jadad score less than 4) trials
suggest no effect of combined therapy on the harm of major
cardiovascular events, myocardial infarction, stroke, and major
bleeding events. The ACTIVE Trial [13], a trial with long-term
follow-up (more than 36 month), suggest that addition of aspirin to
clopidogrel could reduce the harm of major vascular events,
especially stroke, and increase the harm of major bleeding events.
These results were consistent with our study except for the finding
that combined therapy reduces the harm of myocardial infarction,
only 2 trials included in this subset contributed to this lack of
difference, resulting in variation of the conclusion.
In this meta-analysis, benefits were mainly detected in the
prevention of major cardiovascular events, myocardial infarction,
and stroke. However, significant differences in the harm of major
bleeding events were also detected. Furthermore, we noted no
clear effect on revascularization or on vascular or nonvascular
death. Addition of aspirin to clopidogrel therapy reduced the harm
of cardiovascular-related diseases, which may contributed to the
reduction in the harm of total mortality and vascular death, these
effects may be lessened or balanced by the increased harm of
major bleeding events, which contribute to the occurrence of high-
life-threatening events.
Previously published relevant randomized controlled trials
[9,11,21,22,25] supported that aspirin and clopidogrel provided
uniform benefit. The findings of this meta-analysis also suggested
that aspirin plus clopidogrel had a synergistic effect on
cardiovascular outcomes and major bleeding events. These
findings are credible due to the large volume of data available
and the broad range of clinically important features for
participants. However, the main limitation of our research was
that the result is based on published data, where individual patient
data and original data were not available, which limit the capacity
to fully explore effects in subgroups. The second limitation of our
research was that there was no significant difference between
combined aspirin and clopidogrel therapy and clopidogrel therapy
alone in reducing the harm in most cardiovascular events except
for major bleeding. The reason for the lack of difference may be
that only 1 trial provided information for this subset, which limited
the investigation of combined therapy compared to clopidogrel
therapy alone. Furthermore, clopidogrel therapy alone was found
to be superior to aspirin therapy alone in reducing the harm of
major cardiovascular events, myocardial infarction, stroke, and
vascular death, already demonstrated in the CAORIE trial [10],
which may also have contributed to the lack of difference found in
our analysis.
In conclusion, the addition of aspirin to clopidogrel therapy
protected against major cardiovascular events, myocardial infarc-
tion, or stroke, when compared with aspirin therapy alone. It also
increased the harm of major bleeding events, whether compared
with aspirin or clopidogrel therapy. According to previous
findings, the safety profile of drug is of particular importance in
public health recommendations for large, apparently disease-free
populations. The results of this meta-analysis are promising
because we present good evidence that the benefits do not
outweigh the harms. Furthermore, our study could help inform
personally appropriate judgments about their own use of the
combined therapy, and provided evidence to justify general
guidelines advocating the routine use of the combined therapy in
all patients with high cardiovascular harm factors [26–29].
Therefore, we suggest that several factors be improved in future
research: (i) The adverse effect events of clinical trials should be
recorded and reported normatively, especially for the type of
bleeding events, and other non-specific effect adverse reactions
should be evaluated in any future trial. (ii) More attention should
be given to the role of treatment duration and dosage, and optimal
dose and the duration of treatment should be explored. (iii)
Addition of aspirin to clopidogrel therapy should be compared not
only with aspirin therapy alone but also with clopidogrel therapy
alone, which could enable further investigations on the individual
effects of aspirin and clopidogrel. (iv) When both aspirin and
clopidogrel are administrated to patients, bleeding events should
be taken into consideration.
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